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S U M M A R Y
Objectives: To detect, characterize, and assess the genetic clonality of carbapenem-non-susceptible
Enterobacteriaceae in 10 Lebanese hospitals in 2012.
Methods: Selected Enterobacteriaceae isolates with reduced susceptibility to carbapenems were subject
to phenotypic study including antibiotic susceptibility, cloxacillin effect, modiﬁed Hodge test, and
activity of efﬂux pump inhibitor. Carbapenemase genes were detected using PCR; clonal relatedness was
studied by pulsed ﬁeld gel electrophoresis.
Results: Out of 8717 Enterobacteriaceae isolated in 2012, 102 (1.2%) showed reduced susceptibility to
carbapenems. Thirty-one (70%) of the 44 studied clinical isolates harbored blaOXA-48, including 15
Klebsiella pneumoniae, eight Escherichia coli, four Serratia marcescens, three Enterobacter cloacae, and one
Morganella morganii. The majority of OXA-48 producers co-secreted an extended-spectrum beta-
lactamase, while one had an acquired AmpC of the ACC type. In the non-OXA-48 producers, carbapenem
resistance was attributed to the production of acquired AmpC cephalosporinases of MOX or CIT type,
outer membrane impermeability, and/or efﬂux pump overproduction. DNA ﬁngerprints revealed that
OXA-48 producers were different, except for clonal relatedness among four K. pneumoniae, two E. coli,
two E. cloacae, and three S. marcescens.
Conclusions: Nosocomial carbapenem-non-susceptible Enterobacteriaceae are moderately spread in
Lebanon and the predominant mechanism is OXA-48 production.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Enterobacteriaceae are Gram-negative rod-shaped bacteria that
normally colonize the human intestinal tract and are capable of
causing opportunistic infections in both community and hospital
settings. They are easily spread among individuals and can acquireciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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by mobile elements like plasmids and transposons.1 The
dissemination of Enterobacteriaceae producing extended-spec-
trum beta-lactamases (ESBLs) has compromised susceptibility to
cephalosporins in many areas of the world, including Lebanon,
and has increased the consumption of carbapenems.2,3 Recently
developed antibiotics among the class of beta-lactams, carba-
penems (imipenem, meropenem, ertapenem, and doripenem)
are not hydrolysable by EBSLs and represent the antimicrobial
options of last resort.2 In 1993, the ﬁrst incidence of carbapenem
resistance in Enterobacteriaceae was described in Enterobacter
cloacae due to production of carbapenemase NmcA.4 Since then,
various carbapenemases have been detected in Enterobacter-
iaceae and the majority belong to three Ambler classes: (1) class
A, such as KPC, ﬁrst described in the USA but now disseminated
worldwide; (2) class B, such as IMP, VIM, and NDM metallo-
beta-lactamases, encountered in Japan, Taiwan, and Greece, as
well as many European countries; and (3) class D oxacillinases,
such as OXA-48, originating in Turkey and now detected in
Europe and the Mediterranean region.1 Rare acquired cepha-
losporinases of Ambler class C may also show low carbapenem-
hydrolyzing activity.5 Carbapenem resistance in Enterobacter-
iaceae may also arise from non-carbapenemase-mediated
mechanisms, like permeability defects or the impact of efﬂux
transporters.6
In Lebanon, carbapenem-resistant Enterobacteriaceae have been
detected since 2008, with single case reports of OXA-48, IMP-1,
and NDM-1 carbapenemases.7–10 The aims of the current study
were to evaluate the dissemination of carbapenem-resistant
Enterobacteriaceae in various Lebanese hospitals, to identify the
mechanisms of resistance, to examine the types of carbapene-
mases involved in resistance, and to analyze the clonal relationship
of such isolates collected during the year 2012. Part of this work
was presented at the RICAI (Re´union Interdisciplinaire de
Chimiothe´rapie Anti-infectieuse) 2012 congress in Paris, France
(November, 22–23, 2012; abstract number 300).
2. Materials and methods
2.1. Bacterial isolates
From January 1, 2012 to December 31, 2012, carbapenem-
intermediate/resistant isolates of Enterobacteriaceae were collect-
ed from the bacteriology laboratories of 10 Lebanese hospitals
located in diverse geographic areas: Beirut (Hotel Dieu de France,
Saint-George Hospital, Clinique de Levant); Mount Lebanon
(Bellevue Medical Center, Arz Hospital); North Lebanon (Monla
Hospital); South Lebanon (Secours Populaire Libanais, Labib
Medical Center), and Bekaa (Farhat Hospital, Chtaura Hospital).
Using standard disk diffusion testing, and following the recom-
mendations of the European Committee on Antimicrobial Suscep-
tibility Testing (EUCAST),11 strains with inhibition zone diameters
of imipenem smaller than 22 mm, or of ertapenem smaller than
25 mm, were included. These isolates were delivered to the central
microbiology laboratory at the Faculty of Pharmacy, Saint-Joseph
University, Beirut.
2.2. Phenotypic analysis
2.2.1. Antimicrobial susceptibility testing and detection of ESBLs
Antimicrobial susceptibility testing was performed by disk
diffusion on Mueller–Hinton agar plates, according to EUCAST
guidelines.11 Amoxicillin/clavulanic acid (AUG), ceftazidime (CAZ),
cefotaxime (CTX), cefepime (CPM), cefoxitin (FOX), aztreonam
(ATM), and imipenem (IMP) disks (Mast Diagnostics, Merseyside,
UK) were tested. After overnight incubation, an increase in theinhibition zone of the third- and/or fourth-generation cephalospo-
rin disk towards the clavulanate-containing disk by at least 5 mm
was considered as indicating synergy and the presence of an
ESBL.12 The minimum inhibitory concentration of ertapenem
(MICERT) was determined using the Etest (Lioﬁlchem, Roseto degli
Abruzzi, Italy).
2.2.2. Cloxacillin test for detection of AmpC cephalosporinases
Antibiotic susceptibility testing was performed with cloxacillin
(25–500 mg/l) to inhibit AmpC cephalosporinases. An increase in
susceptibility to cephalosporins in the presence of cloxacillin was
considered to be due to AmpC production. The cloxacillin test was
also used to allow better visualization of synergy between: (1)
clavulanic acid and third- and/or fourth-generation cephalospor-
ins, indicating the possibility of ESBL production, and (2) clavulanic
acid and imipenem, indicating the production of an ESBL with
carbapenem-hydrolyzing activity.12
2.2.3. Modiﬁed Hodge test
A modiﬁcation of the Hodge test was applied to screen for
carbapenemase production.13 The indicator organism, Escher-
ichia coli ATCC 25922 at a turbidity of 0.5 McFarland, was used
to inoculate the surface of Mueller–Hinton agar plates, and a
10 mg meropenem disk (Mast Diagnostics, Merseyside, UK) was
placed at the center. The test strain was heavily streaked from
the disk to the plate periphery. After overnight incubation, the
presence of a cloverleaf-shaped indentation of growth of the test
strain versus the indicator strain was interpreted as carbape-
nemase production, with the highest sensitivity to those
belonging to Ambler classes A and D.14 Heavy streaks of
carbapenemase-positive and carbapenemase-negative strains
were used as internal controls.
2.2.4. Activity of efﬂux pump inhibitor
Mueller–Hinton plates containing 100 mg/l of efﬂux pump
inhibitor phenylalanine–arginine b-naphthylamide hydrochloride
(PAbN; Sigma-Aldrich, USA) were prepared. Selected isolates were
swabbed on plates with and without PAbN, and Etest strips of
ertapenem, ceﬁxime, and levoﬂoxacin (Lioﬁlchem, Via Scozia,
Italy) were placed on the plates. After overnight incubation at
37 8C, MICs in the presence and the absence of the inhibitor were
compared, and a two-fold decrease in MIC in the presence of PAbN
was considered as indicative of efﬂux activity.15,16 E. coli ATCC
25922 was used as internal control.
2.3. Genotypic analysis
The presence of various types of beta-lactamase genes was
screened for by PCR using primers designed by the Institut
Pasteur, Unite´ des Agents Antibacte´riens, Paris, France.17 When
ESBLs were detected by phenotypic tests, PCR experiments to
detect blaCTX-M group 1 and blaSHV genes were performed. When
hyperproduction of AmpC was suspected by the cloxacillin test,
multiplex PCR for plasmid-encoded AmpC genes was performed,
including blaACC, blaFOX, blaMOX, blaDHA, blaCIT, and blaEBC. To detect
carbapenemases, strains were tested for blaKPC, blaGES, blaOXA-48,
blaVIM, blaIMP-1, blaIMP-2, and blaNDM genes. For OXA-48 producers,
the presence of insertion sequence IS1999 of transposon Tn1999
known to carry the blaOXA-48 gene was investigated, as described
by Aubert et al.18
2.3.1. Conjugation experiments with Klebsiella pneumoniae
Conjugation experiments were performed with K. pneumoniae
Kpd2, using the recipient nalidixic acid-resistant E. coli K12, as
described previously,19 but changing the mating broth medium to
brain–heart infusion.
Table 1
Numbers and percentages of carbapenem-non-susceptible Enterobacteriaceae
(CNE) collected from 10 participating hospitals in different areas of Lebanon
during the year 2012
Species Total Number (%) of CNEa
Klebsiella pneumoniae 1826 26 (1.4)
Escherichia coli 6631 51 (0.8)
Enterobacter cloacae 513 12 (2.3)
Serratia sppb 199 11 (5.5)
Morganella morganii 229 2 (0.9)
Salmonella spp 87 1 (1.1)
All Enterobacteriaceae 8717 102 (1.2)
a The percentage for each species indicates the proportion of CNE among total
isolated strains within the same species.
b Serratia marcescens and Serratia odorifera.
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Genomic DNA digested with XbaI (Roche, Meylan, France) was
subjected to pulsed ﬁeld gel electrophoresis (PFGE) using a
clamped homogeneous electric-ﬁeld apparatus (CHEF-DRII, Bio-
Rad). Bionumerics (Applied Math, Kortrijk, Belgium) was used to
establish a similarity matrix for the DNA based on calculation of
the Dice coefﬁcient (pairwise comparison of strains). A dendro-
gram was generated with the unweighted pair group using
arithmetic means (UPGMA) hierarchical algorithm. Gels were
compared using Staphylococcus aureus NCTC 8325 as a reference
strain. PFGE patterns were interpreted according to international
recommendations.20
3. Results
Out of 8717 Enterobacteriaceae isolated in 2012, 102 (1.2%) non-
duplicate carbapenem-non-susceptible strains were reported in
the records of the participating hospitals (Table 1). The distribution
of the 102 strains among hospitals was as follows: 31 were from
Hotel Dieu de France, 32 from Saint-George Hospital, six from
Clinique de Levant, two from Bellevue Medical Center, two from
Arz Hospital, one from Monla Hospital, 27 from Farhat Hospital,
and one from Chtaura Hospital. Of these, only 44 isolates were
delivered to the central laboratory. The studied species and
corresponding hospital sources are shown in Figure 1. Twenty-two
specimens were isolated from urine, 10 from sputum, four from
pus, four from wound swabs, two from blood, one from stool, and
one from pleural ﬂuid. Eighteen isolates out of 44 were nosocomial.
The results of disk diffusion tests and MICs of ertapenem are
shown in Table 2. Isolates of K. pneumoniae and E. coli displayed
ertapenem-susceptible (MICERT 0.5 mg/l), intermediate (MICERT
>0.5–1 mg/l), or resistant (MICERT >1 mg/l) phenotypes, concur-
rent either with sensitivity or resistance to tested cephalosporinsFigure 1. Distribution of the tested carbapenem-non-susceptible Enterobacteriaceae stra
France; SG, Saint-George Hospital; BMC, Bellevue Medical Center; AH, Arz Hospital; CLand aztreonam. All E. cloacae were resistant to ertapenem, tested
cephalosporins, and aztreonam. Serratia marcescens, Serratia
odorifera, and Salmonella enterica subsp. arizonae were highly
resistant to the beta-lactams tested, while the Morganella morganii
isolate was resistant to cephalosporins and aztreonam but
intermediate to carbapenems.
Synergy between amoxicillin/clavulanic acid and third/fourth-
generation cephalosporins was observed for 31 strains including
11 K. pneumoniae, six E. coli, nine E. cloacae, four S. marcescens, and
one M. morganii. These isolates were candidates for ESBL gene
detection. None of the isolates displayed synergy between
amoxicillin/clavulanic acid and imipenem, indicating the absence
of ESBLs with carbapenem-hydrolyzing activity. Moreover,
synergy between amoxicillin/clavulanic acid and third/fourth-
generation cephalosporins was better visualized on cloxacillin-
containing media for the majority of the 31 strains described
above.
Inhibition zones of third/fourth-generation cephalosporins
(CAZ, CTX, and CPM) on Mueller–Hinton agar plates with 25–
500 mg/l of cloxacillin increased for two K. pneumoniae and two E.
coli, indicating the possibility of production of an acquired AmpC
cephalosporinase. E. cloacae, S. marcescens, and M. morganii
naturally produce chromosomal AmpC beta-lactamases and
hyperproduction can be induced by exposure to beta-lactams.21
In two out of nine E. cloacae strains, three out of ﬁve Serratia
strains, and in M. morganii, the cloxacillin test was positive. In the
remaining strains, the test was negative, possibly due to a lack of
hyperproduction of a chromosomal AmpC, or to masking by co-
production of an ESBL or a carbapenemase.
The cloverleaf-like growth pattern in the modiﬁed Hodge test
was positive for 35 strains including 15 K. pneumoniae, eight E. coli,
seven E. cloacae, four S. marcescens, and one M. morganii.
3.1. OXA-48-producing strains
Out of 44 tested Enterobacteriaceae, 31 (70.4%) harbored OXA-
48, including 15 K. pneumoniae, eight E. coli, three E. cloacae, four S.
marcescens, and one M. morganii. Of the 31 OXA-48 producers, 28
(90.3%) carried IS1999. In addition to OXA-48, 20 (64.5%) isolates
had an ESBL of CTX-M group 1 type, including 11 K. pneumoniae,
ﬁve E. coli, three E. cloacae, and one M. morganii. In Serratia, the four
(12.9%) OXA-48-positive isolates were also positive for an ESBL of
the SHV type. In all these strains with both carbapenemase and
ESBL enzymes, there was non-susceptibility to third-generation
cephalosporins in addition to ertapenem. One K. pneumoniae
harbored OXA-48 with an acquired AmpC of the ACC type. In
conjugation experiments, OXA-48 was not transferable to recipient
E. coli K12.ins collected during the study by species and hospital source (HDF, Hotel Dieu de
, Clinique de Levant; FH, Farhat Hospital; MH, Monla Hospital.).
Table 2










AMC FOX CTX FEP CAZ ATM IMP MICERT
(mg/l)
K. pneumoniae 17 I (1) Neg MOX Neg Neg R R R S R R I 0.25
II (1) Neg ACC OXA-48 Pos R R I I S S R >32
III (11) CTX-M1 Neg OXA-48 Pos R R R R R R R >32
IV (3) Neg Neg OXA-48 Pos R I/R I S S/I S/I I/R (0.75–32)
V (1) Neg Neg Neg Neg R R R R R R R >32
E. coli 11 I (1) Neg CIT Neg Neg R R R I R R I 0.5
II (1) CTX-M1 CIT Neg Neg R R R I R R I >32
III (5) CTX-M1 Neg OXA-48 Pos R I/R R R I/R R I/R (1–>32)
IV (3) Neg Neg OXA48 Pos R I S S S/I S I (0.5–1)
V (1) Neg Neg Neg Neg R R R R R R R >32
E. cloacae 9 I (3) CTX-M1 Neg OXA48 Pos R R R R R R R >32
II (6) 1 CTX-M1
1 SHV
4 Neg
Neg Neg 4 Pos
2 Neg
R R R R R R I/ R (2–>32)
S. marcescens 4 I (4) SHV Neg OXA-48 Pos R R R R R R R >32
S. odorifera 1 I (1) Neg Neg Neg Neg R R R R R R R >32
M. morganii 1 I (1) CTX-M1 Neg OXA-48 Pos R R R R R R I 0.75
S. enterica subsp.
arizonae
1 I (1) Neg Neg Neg Neg R R R R R R R >32
ESBL, extended-spectrum beta-lactamase; AMC, amoxicillin/clavulanic acid; FOX, cefoxitin; CTX, cefotaxime; FEP, cefepime; CAZ, ceftazidime; ATM, aztreonam; IMP,
imipenem; MICERT, minimum inhibitory concentration of ertapenem; S, sensitive; I, intermediate; R, resistant.
a K. pneumoniae = Klebsiella pneumoniae; E. coli = Escherichia coli; E. cloacae = Enterobacter cloacae; S. marcescens = Serratia marcescens; S. odorifera = Serratia odorifera; M.
morganii = Morganella morganii; S. enterica = Salmonella enterica.
Figure 2. Dendrogram of DNA macrorestriction patterns of OXA-48-producing
Enterobacteriaceae with XbaI. Strains were clustered by the unweighted pair-group
method of arithmetic averages (UGPMA).
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strains are presented in Figure 2. Data show the existence of
clonally related strains among K. pneumoniae (4/15 isolates), E. coli
(2/8 isolates), E. cloacae (2/3 isolates), and S. marcescens (3/4
isolates). The clonally related K. pneumoniae and E. coli were
isolated from different hospitals.
3.2. Acquired AmpC-producing strains
Various acquired AmpC enzymes belonging to the groups MOX,
ACC, and CIT were detected. One K. pneumoniae harbored MOX and
another harbored ACC along with carbapenemase OXA-48. CIT was
detected in two E. coli isolates; one of these also expressed an ESBL
of CTX-M group 1 type.
3.3. Ertapenem resistance and efﬂux activity
Eleven isolates with a high level of resistance to ertapenem
were subjected to the efﬂux inhibition test. These included one K.
pneumoniae genotype V, two E. coli genotypes II and V, six E. cloacae
genotype II, S. odorifera genotype II, and S. enterica subsp.
arizonae. Ertapenem MICs were reduced by two-fold in six isolates
that revealed a negative modiﬁed Hodge test, indicating the
possibility of efﬂux pump activity in the absence of carbapene-
mase. These included one K. pneumoniae genotype V, four E. cloacae
genotype II, and S. odorifera genotype II. The efﬂux test, however,
was negative in three isolates (one E. coli genotype V, one E. cloacae
genotype II, and S. enterica subsp. arizonae) eliminating efﬂux as a
mechanism of ertapenem resistance in these strains and suggest-
ing the possibility of outer membrane protein mutation. The two
remaining isolates, one E. coli genotype II and one E. cloacae
genotype II, did not grow in the presence of the inhibitor; the test
was inconclusive.
4. Discussion
Although several studies have addressed the issue of the
emergence of carbapenem-non-susceptible pathogens worldwide,
no epidemiological survey has been carried out in Lebanon,
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study represents the ﬁrst broad surveillance of carbapenem-non-
susceptible Enterobacteriaceae isolated from Lebanese hospitals. It
also represents the ﬁrst report of acquired AmpC enzymes in
Lebanon.
The overall prevalence of carbapenem-non-susceptible Enter-
obacteriaceae in Lebanon during 2012 was 1.2%. If compared to the
4.2% reported by the Centers for Disease Control and Prevention
(CDC) in the year 2011, carbapenem resistance in Enterobacter-
iaceae in Lebanon appears modest.22 Concerning the distribution of
carbapenem resistance among enterobacterial species, the Euro-
pean network on carbapenemases reported in 2012 that carba-
penemase producers in Europe are mainly identiﬁed among K.
pneumoniae and E. coli; the prevalence for K. pneumoniae was found
to vary signiﬁcantly, from very high in Greece (59.9%) to low in
Germany (0.2%).23 In this study, carbapenem resistance was
disseminated among different enterobacterial species including K.
pneumoniae, E. coli, E. cloacae, S. marcescens, and M. morganii. With
the exception of Serratia spp, resistance ranged from 0.8% for E. coli
to 2.3% for E. cloacae. With regard to Serratia spp, 10 out of the
11 non-susceptible strains isolated during 2012 originated from a
single hospital, likely indicating a limited epidemic.
OXA-48 carbapenemase was the prominent mediator of
carbapenem resistance in Lebanese hospitals. The detection of
OXA-48 among K. pneumoniae and E. coli is in agreement with other
data reported in Lebanon.7,10 Since the ﬁrst description of OXA-48-
producing K. pneumoniae in Turkey, numerous reports have
indicated its dissemination to Mediterranean countries including
France, Egypt, Tunisia, and Morocco.8,24–27 No other carbapene-
mases were detected among Enterobacteriaceae strains in this
study. According to our results, the metallo-beta-lactamases NDM-
1 and IMP-1 previously detected in case reports in Lebanon did not
propagate to Lebanese patients.9,10 Also, although KPC is now
endemic in Israel, it was not detected in this study.28 This may
indicate that the spread of carbapenemases of classes A and B
among isolates of Enterobacteriaceae in Lebanon is still restricted,
unlike that of OXA-48.
All isolates producing OXA-48 were associated with a positive
modiﬁed Hodge test. This is consistent with previous data
indicating that the test shows excellent sensitivity for the
detection of carbapenem resistance mediated via the production
of class D carbapenemases.29 However, the test may lack
sensitivity in Enterobacter species;25 this may explain the false-
positive results in four E. cloacae of genotype II, which were OXA-
48-negative but modiﬁed Hodge test-positive. In this study, the
majority of OXA-48 producers harbored insertion sequence IS1999
suggesting horizontal transfer of the blaOXA-48 gene. However,
conjugation experiments were not efﬁcient, which is indicative of
probable blaOXA-48 chromosomal integration, as reported previ-
ously.30,31
To test the genetic relatedness of the strains, PFGE allowed the
comparison of the genome of the blaOXA-48-positive Enterobacter-
iaceae obtained from different hospitals. For each species, certain
strains were clonally related, indicating that clonal dissemination
played a role in the overall spread of blaOXA-48. The results of PFGE
for OXA-48-producing K. pneumoniae and E. coli strains revealed
high genetic diversity. OXA-48-producing E. cloacae and S.
marcescens strains demonstrating genetic relatedness originated
from the same hospitals, revealing small institutional-level out-
breaks. In order to obtain a better analysis of clonality in these two
genera, greater sampling from different hospital sources is needed.
In non-OXA-48 producers, acquired AmpC enzyme alone (K.
pneumoniae genotype I and E. coli genotype I) conferred only
intermediate resistance to imipenem. Like chromosomal AmpC,
the plasmid-encoded AmpC enzymes slightly affect carbapenem
susceptibility.5 However, carbapenem resistance can arise inclinical isolates where AmpC enzymes or ESBLs exist together
with lower permeability, like in E. coli genotype II.32 Indeed, the
emergence of resistance to carbapenems can, in part, be due to the
loss or alteration of outer membrane porins.33 This could be the
case in samples in which no investigated carbapenems of classes A,
B, or D have been detected, like E. coli genotype V. In K. pneumoniae
genotype V and S. odorifera, highly resistant to both cephalosporins
and carbapenems, no beta-lactamase genes were detected. Efﬂux
pump inhibitor tests were positive, indicating a beta-lactamase-
independent resistance mechanism. In contrast, in S. enterica
subsp. arizonae, neither beta-lactamase genes nor the efﬂux
inhibition test were positive, suggesting the existence of mutant
outer membrane proteins.
In conclusion, carbapenem-non-susceptible Enterobacteriaceae
are moderately spread in Lebanese hospitals and resistance
depends predominantly on OXA-48 production. A combination
of AmpC production, efﬂux pump overexpression, and/or mutant
porin proteins may also play a role in carbapenem resistance. As
the reservoirs of OXA-48 producers are growing worldwide,
concerted surveillance and infection control measures are needed
for the containment of further dissemination in Lebanon.
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